The role of primary retroperitoneal lymph node dissection in the treatment of stage II seminoma.

ABSTRACT:

Purpose of review

Stage II seminoma is responsive to chemo- or radiotherapy with a progression-free survival of 87-95% at 5 years but at the cost of short- and long-term toxicity. After evidence about these long-term morbidities emerged, four surgical cohorts investigating the role of retroperitoneal lymph node dissection (RPLND) as a treatment option for stage II disease were initiated.

Recent findings

Currently, two RPLND series have been published as a complete report, while data from other series have only been published as congress abstracts. In series without adjuvant chemotherapy, recurrence rates ranged from 13% to 30% after follow-ups of 21-32 months. In those receiving RPLND and adjuvant chemotherapy, the recurrence rate was 6% after a mean follow-up of 51 months.

SUBMITTER: Sigg S 

PROVIDER: S-EPMC10256310 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature